Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-02-28
Intellia Therapeutics, Inc.
Clinical-stage biotech developing in vivo CRISPR gene-editing medicines led by lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A single Phase 3 readout can create a launch company
The 5-year setup is a pivot from collaboration revenue to a first commercial franchise if mid-2026 data and a 2026 filing stay on track. Upside becomes non-linear if the second program’s regulatory path clears, but permissioning is the main fragility.

Analysis

Thesis
If lonvo-z’s mid-2026 Phase 3 data supports a 2H26 filing and a 2027 launch, NTLA can jump from “collaboration revenue” to a durable rare-disease franchise by building payer-verified outcomes contracts + high-trust patient routing; nex-z is the non-linear upside option, but also the main regulatory fragility.
Last Economy Alignment
AI makes R&D iteration and monitoring cheaper, but the scarce asset here is regulator-trusted human outcomes data + safety playbooks; value rises if NTLA turns safety/compliance into a repeatable launch engine, and collapses if permissioning (holds/labels) stays the bottleneck.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
7.6x (from 5 most recent analyses)
Reasoning
The re-rate is a de-risking ladder: (1) lonvo-z Phase 3 data, (2) a clean filing/acceptance, (3) a launch that solves one-time-therapy reimbursement with outcomes-linked contracts and fast coverage decisions. If NTLA executes distribution (treating-center onboarding + patient services + real-world evidence) and keeps nex-z progressing at least in ATTRv-PN, the market can treat it as a “launch platform” rather than a single-asset bet, supporting a mid-single-digit billions EV by 2031.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The dominant risk is regulatory permissioning after liver-safety signals (especially for nex-z), which can delay or narrow value capture. Second is commercial conversion risk for a one-time edit (coverage mechanics, site workflow, long-term follow-up obligations). Third is financing/dilution risk if timelines slip while the company is staffing for launch.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.19
They control proprietary clinical outcomes data and development know-how that becomes more valuable as AI makes analysis cheap. The threat is not an app competitor—it’s regulators stopping dosing and payers slowing adoption for an irreversible therapy.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$22.95
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case